%0 Journal Article
%A Jost, Stefanie T.
%A Visser-Vandewalle, Veerle
%A Rizos, Alexandra
%A Loehrer, Philipp A.
%A Silverdale, Monty
%A Evans, Julian
%A Samuel, Michael
%A Petry-Schmelzer, Jan Niklas
%A Sauerbier, Anna
%A Gronostay, Alexandra
%A Barbe, Michael T.
%A Fink, Gereon Rudolf
%A Ashkan, Keyoumars
%A Antonini, Angelo
%A Martinez-Martin, Pablo
%A Chaudhuri, K. Ray
%A Timmermann, Lars
%A Dafsari, Haidar S.
%A Bhidayasiri, Roongroj
%A Falup-Pecurariu, Cristian
%A Jeon, Beomseok
%A Leta, Valentina
%A Borghammer, Per
%A Odin, Per
%A Schrag, Anette
%A Storch, Alexander
%A Violante, Mayela Rodriguez
%A Weintraub, Daniel
%A Adler, Charles
%A Barone, Paolo
%A Brooks, David J.
%A Brown, Richard
%A Cantillon, Marc
%A Carroll, Camille
%A Coelho, Miguel
%A Henriksen, Tove
%A Hu, Michele
%A Jenner, Peter
%A Kramberger, Milica
%A Kumar, Padma
%A Kurtis, Mónica
%A Lewis, Simon
%A Litvan, Irene
%A Lyons, Kelly
%A Martino, Davide
%A Masellis, Mario
%A Mochizuki, Hideki
%A Morley, James F.
%A Nirenberg, Melissa
%A Pagonabarraga, Javier
%A Panicker, Jalesh
%A Pavese, Nicola
%A Pekkonen, Eero
%A Postuma, Ron
%A Rosales, Raymond
%A Schapira, Anthony
%A Simuni, Tanya
%A Stocchi, Fabrizio
%A Subramanian, Indu
%A Tagliati, Michele
%A Tinazzi, Michele
%A Toledo, Jon
%A Tsuboi, Yoshio
%A Walker, Richard
%T Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease
%J npj Parkinson's Disease
%V 7
%N 1
%@ 2373-8057
%C London [u.a.]
%I Nature Publ. Group
%M FZJ-2021-02551
%P 48
%D 2021
%X To identify predictors of 36-month follow-up quality of life (QoL) outcome after bilateral subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson’s disease (PD). In this ongoing, prospective, multicenter international study (Cologne, Manchester, London) including 73 patients undergoing STN-DBS, we assessed the following scales preoperatively and at 6-month and 36-month follow-up: PD Questionnaire-8 (PDQ-8), NMSScale (NMSS), Scales for Outcomes in PD (SCOPA)-motor examination, -activities of daily living, and -complications, and levodopa equivalent daily dose (LEDD). We analyzed factors associated with QoL improvement at 36-month follow-up based on (1) correlations between baseline test scores and QoL improvement, (2) step-wise linear regressions with baseline test scores as independent and QoL improvement as dependent variables, (3) logistic regressions and receiver operating characteristic curves using a dichotomized variable “QoL responders”/“non-responders”. At both follow-ups, NMSS total score, SCOPA-motor examination, and -complications improved and LEDD was reduced significantly. PDQ-8 improved at 6-month follow-up with subsequent decrements in gains at 36-month follow-up when 61.6% of patients were categorized as “QoL non-responders”. Correlations, linear, and logistic regression analyses found greater PDQ-8 improvements in patients with younger age, worse PDQ-8, and worse specific NMS at baseline, such as ‘difficulties experiencing pleasure’ and ‘problems sustaining concentration’. Baseline SCOPA scores were not associated with PDQ-8 changes. Our results provide evidence that 36-month QoL changes depend on baseline neuropsychological and neuropsychiatric non-motor symptoms burden. These findings highlight the need for an assessment of a wide range of non-motor and motor symptoms when advising and selecting individuals for DBS therapy.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ 34103534
%U <Go to ISI:>//WOS:000659233200001
%R 10.1038/s41531-021-00174-x
%U https://juser.fz-juelich.de/record/893091